Form 4 for BRKR BRUKER CORP
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-05 · accession 0001544635-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-06 | 2026-01-05 | BRKR | Munch Mark | EVP, Pres BRUKER NANO INC | S - Sale+OE | $49.66 | -33.8K | 128.4K | -21% | -$1.68M |
| DM | 2026-01-06 | 2026-01-05 | BRKR | Munch Mark | EVP, Pres BRUKER NANO INC | M - OptEx | $22.19 | +33.8K | 132.9K | +34% | +$751.0K |
| DM | 2026-01-06 | 2026-01-05 | BRKR | Munch Mark | EVP, Pres BRUKER NANO INC | M - OptEx | $0.00 | -33.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-05 | S | D | 4,506 | $50.00 | 157,780 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-01-05 | M | A | 15,337 | $22.19 | 162,286 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-05 | M | A | 14,000 | $22.19 | 146,949 | D | — | — | |
| 4 | Common | Common Stock | 2026-01-05 | M | A | 4,506 | $22.19 | 132,949 | D | — | — | |
| 5 | Common | Common Stock | 2026-01-05 | S | D | 14,000 | $50.00 | 143,780 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| 6 | Common | Common Stock | 2026-01-05 | S | D | 15,337 | $49.25 | 128,443 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.74 to $50.065, inclusive. The reporting person undertakes to provide to Bruker Corporation, any security holder of Bruker Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Stock Option (Right to Purchase) | 2026-01-05 | M | D | 14,000 | $0.00 | 40,337 | D | $22.19 · — to 2026-10-04 | 14,000 Common Stock | (F4) The stock option granted to the Reporting Person on October 4, 2016 (the "Original Grant Date") vests in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date. |
| 8 | Derivative | Stock Option (Right to Purchase) | 2026-01-05 | M | D | 15,337 | $0.00 | 25,000 | D | $22.19 · — to 2026-10-04 | 15,337 Common Stock | (F4) The stock option granted to the Reporting Person on October 4, 2016 (the "Original Grant Date") vests in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date. |
| 9 | Derivative | Stock Option (Right to Purchase) | 2026-01-05 | M | D | 4,506 | $0.00 | 0 | D | $22.19 · — to 2026-10-04 | 4,506 Common Stock | (F3) The stock option granted to the Reporting Person on October 4, 2016 (the "Original Grant Date") vests in full on the fourth anniversary of the Original Grant Date. |